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OBJECTIVES The aim of this research was to determine whether presence of atrial fibrillation (AF) provides
incremental prognostic information relative to myocardial perfusion single-photon emission
computed tomography (MPS) with respect to risk of cardiac death (CD).
BACKGROUND The prognostic significance of AF in patients undergoing MPS is not known.
METHODS A total of 16,048 consecutive patients undergoing MPS were followed-up for a mean of 2.21
 1.15 years for the development of CD. Of those, 384 patients (2.4%) had AF. Cox
proportional hazards method was used to compare clinical and perfusion data for the
prediction of CD in patients with and without AF.
RESULTS Atrial fibrillation was a significant predictor of CD in patients with normal (1.6% per year vs.
0.4% per year in non-AF patients), mildly abnormal (6.3% per year vs. 1.2% per year), and
severely abnormal MPS (6.4% per year vs. 3.7% per year) (p 0.001 for all). By multivariable
analysis, AF patients had worse survival (p  0.001) even after adjustment for the variables
most predictive of CD: age, diabetes, shortness of breath, use of vasodilator stress, rest heart
rate, and the nuclear variables. In the 4,239 patients with left ventricular ejection fraction
evaluated by gated MPS, AF demonstrated incremental prognostic value not only over clinical
and nuclear variables, but also over left ventricular ejection in predicting CD (p  0.014).
CONCLUSIONS The presence of AF independently increases the risk of cardiac events over perfusion and
function variables in patients undergoing MPS. Patients with AF have a high risk of CD,
even when MPS is only mildly abnormal. Whether patients with AF and mildly abnormal
MPS constitute a group more deserving of early referral to cardiac catheterization is a
question warranting further study. (J Am Coll Cardiol 2004;44:1062–70) © 2004 by the
American College of Cardiology Foundations
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dtrial fibrillation (AF) is the most common sustained
ardiac arrhythmia, accounting for approximately one-third
f hospitalizations for rhythm disturbances (1). While the
revalence of AF in modern Western society is 1% in
hose younger than 60 years of age, it exceeds 6% in those
lder than 80 years of age (2–4). It has been estimated that
.2 million Americans have paroxysmal or persistent AF (5),
nd it is predicted that the prevalence of AF will increase
.5-fold in the next 50 years (6). The mortality rate of
atients with AF is almost double that of patients in normal
inus rhythm; it is linked to the severity of underlying heart
isease (2,7–9), and is attributed mainly to an increased
ardiac death (CD) rate per se (mostly due to heart failure),
ather than to thromboembolism (10). Myocardial perfusion
From the Departments of Imaging (Division of Nuclear Medicine) and Medicine
Division of Cardiology), Cedars-Sinai Medical Center, Los Angeles, California;
Cardiovascular Division, Department of Medicine, Keck School of Medicine,
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n part, by a grant from Bristol-Myers Squibb Medical Imaging and a grant from
ujisawa Heathcare. Dr. Abidov is a Save a Heart Foundation Research Fellow at
edars-Sinai Medical Center, Los Angeles, California. Dr. Kim Williams acted as
he guest editor for this paper.
Manuscript received February 25, 2004; revised manuscript received April 22,a004, accepted May 25, 2004.ingle-photon emission computed tomography (MPS) is
ffective for risk-stratification of patients with known or
uspected coronary artery disease (11–17), but the impact of
F on the prognostic implications of MPS has virtually not
een studied. Accordingly, the aim of our study was to
ssess whether the presence of AF provides incremental
rognostic information in patients undergoing MPS with
espect to risk of CD.
ETHODS
tudy population. Initial study population was comprised
f 18,291 consecutive patients who underwent dual-isotope
rest 201Tl/stress 99mTc sestamibi) MPS with exercise or
asodilator (dipyridamole or adenosine) stress testing be-
ween January 1991 and December 1998 at Cedars-Sinai
edical Center. Patients with known valvular heart disease
nd/or nonischemic cardiomyopathy were excluded based
n the results of patient’s history, physical examination, and
vailable medical records, including hospital files. Of the
nitial population, 784 patients (4.2%) were lost to follow-
p. In addition, 1,459 patients with early coronary artery
ypass grafting or percutaneous coronary intervention 60
ays after the index MPS were censored from survival
nalysis because their referral to revascularization may have
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September 1, 2004:1062–70 Atrial Fibrillation and Prognosis in SPECTeen influenced by their scan results (18,19). For the
urpose of prognostic assessment, the final population
ncluded 16,048 patients, of whom 384 patients (2.4%) had
F and 15,664 did not. We defined the AF population as
atients with AF on the baseline resting electrocardiogram
ECG) on the day of MPS. All other patients were
onsidered as the non-AF population. In our study, we
ompared clinical, nuclear, and prognostic data of AF
atients to the non-AF patients (Table 1).
maging procedure. All patients underwent rest 201Tl/
tress 99mTc-sestamibi MPS as previously described
20).Whenever possible, beta-blockers and calcium-channel
ntagonists were terminated 48 h before testing and nitrates
t least 6 h before testing. Patients performed a symptom-
imited exercise treadmill test (18,19,21) or vasodilator
intravenous dipyridamole or adenosine infusion) stress
sing standard protocols (17,22). Patients were instructed
ot to consume coffee or other products containing caffeine
or 24 h before the test. The ECG was monitored contin-
ously in three leads (aVF, V1, and V5), and 12-lead ECGs
ere obtained at rest, during each stage of exercise, and
ostexercise to assess for arrhythmias or ischemic ST-
egment deviation (22). Nondiagnostic ECG response was
efined as presence of the significant resting ST-T abnor-
Abbreviations and Acronyms
AF  atrial fibrillation
CD  cardiac death
LVEF  left ventricular ejection fraction
MPS  myocardial perfusion single-photon emission
computed tomography
SDS  summed difference (stress-rest) perfusion score
SPECT  single-photon emission computed tomography
SRS  summed rest score
SSS  summed stress score
Table 1. Clinical Characteristics of the Study P
Parameters
Gender (male)
Age (mean  SD)
Vasodilator stress
Prior MI
Prior CABG
Prior PCI
Hypertension
Diabetes
SOB
Angina
Non-diagnostic ECG
Resting tachycardia (rest HR 100 beats/min)
Beta-blockers*
Calcium-channel blockers*
Digoxin*
*Under influence at the time of testing.
AF atrial fibrillation; Angina typical or atypical angin
rate; Nondiagnostic ECG  significant resting ST-T abno
nondiagnostic; MI  myocardial infarction; PCI  percutaneousalities, in which the response to exercise would be con-
idered nondiagnostic. Blood pressure was measured and
ecorded at rest, at the end of each stress stage, and at peak
tress.
cquisition protocol. All patients underwent separate
cquisition, dual isotope MPS (20). Rest 201Tl MPS was
tarted 10 min after injection of radiotracer. During
maging two energy windows were used: 30% centered
ver the 68 to 80 keV energy peak and 20% centered over
he 167 keV energy peak. 99mTc-sestamibi MPS was
nitiated 60 min after injection and employed single 15%
indow, centered on the 140 keV peak; MPS was
erformed with a circular or elliptical 180° acquisition for
4 projections at 20 to 25 s/projection for 201Tl (3.0 to
.5 mCi) and at 15 to 25 s/projection for 99mTc-sestamibi
25 to 40 mCi). All images were subject to quality control
easures. The projection data were reconstructed into
omographic transaxial images using filtered backprojec-
ion and automatic reorientation (23,24). No attenuation
r scatter correction was used.
In 4,239 patients (26.4% of the study population),
-frame gated SPECT imaging (100% acceptance window)
as performed to assess left ventricular ejection fraction
LVEF) (25); only technically satisfactory gated LVEF
tudies were reported and included in the database.
mage interpretation. Semiquantitative visual interpreta-
ion was performed using the 20-segment model (11,20).
ach segment was scored using a 5-point scoring system
0  normal, 1  equivocal, 2  moderate, 3  severe
eduction of radioisotope uptake, and 4  absence of
etectable tracer uptake in a segment). Summed stress
SSS), rest (SRS), and rest-stress difference (SDS) scores
ere obtained by summing the individual scores of the 20
egments (20). These indexes were converted to percent of
he total myocardium (% Myo) (26) involved with stress
lation
F Group
 384)
Non-AF Group
(n  15,664) p Value
4 (63.5%) 9,264 (59.1%) 0.083
.3  9.1 65.0  12.5 0.001
4 (55.7%) 4,992 (31.9%) 0.001
7 (22.8%) 3,263 (21.4%) 0.514
6 (17.3%) 2,063 (13.6%) 0.035
1 (10.8%) 1,940 (12.6%) 0.290
6 (56.3%) 7,380 (47.1%) 0.001
0 (18.2%) 2,307 (14.7%) 0.056
0 (15.6%) 819 (5.2%) 0.001
6 (38.0%) 6,586 (42.0%) 0.114
3 (81.5%) 6,266 (40.0%) 0.001
2 (21.9%) 241 (2.5%) 0.001
4 (8.9%) 1,413 (9.0%) 0.910
1 (13.3%) 1,877 (12.0%) 0.439
7 (46.1%) 883 (5.6%) 0.001
story; CABG coronary artery bypass grafting; HR heart
ies, in which the response to exercise would be consideredopu
A
(n
24
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8
6
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4
3
5
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a by hi
rmalitcoronary intervention; SOB  shortness of breath.
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Atrial Fibrillation and Prognosis in SPECT September 1, 2004:1062–70% Myo stress, from SSS), ischemic (% Myo ischemic, from
DS), or fixed defects (% Myo fixed, from SRS) by dividing
he summed scores by 80, the maximum potential score in
he 20-segment model (4  20), and multiplying by 100.
yocardial perfusion SPECT results were categorized us-
ng % Myo stress; % Myo stress 5 was considered as
ormal, % Myo stress  5 to 10 as mildly abnormal, and %
yo stress 10 as moderately to severely abnormal
PS (27).
In those patients who had gated SPECT performed,
ated short-axis images were processed using quantitative
ated SPECT software (QGS, Cedars-Sinai Medical Cen-
er, Los Angeles, California), and the LVEF was automat-
cally calculated (28).
atient follow-up. Specifically dedicated research person-
el, blinded to the clinical and MPS test results, performed
ll follow-up-related procedures (11). The follow-up dura-
ion was 1 year for all study population patients. Patients
ere followed-up for CD or nonfatal myocardial infarction.
ardiac death was defined as death attributable to any
ardiac cause (e.g., lethal arrhythmia, myocardial infarction,
r congestive heart failure) as confirmed by review of death
ertificate and medical records. All other death was consid-
red noncardiac. Known stroke-related death was not con-
idered CD. Non-fatal myocardial infarction was docu-
ented by appropriate ECG and cardiac enzyme level
hanges. If both events were found in a patient, only CD
as considered as follow-up event. We also collected
nformation regarding the non-cardiac mortality in the
tudy population.
tatistical analysis. All continuous variables are expressed
s means  SD. The mean differences for continuous
ariables were compared using the Student t test (two-
ailed) or analysis of variance (in case of multiple compari-
ons). Categorical variables were compared using a chi-
quare statistic. A p value 0.05 was considered significant;
here appropriate, 95% confidence intervals were employed.
Unadjusted as well as adjusted CD rates were assessed.
or the latter, Cox proportional hazards analysis was
pplied to determine the independent prognostic value of
linical, historical, and nuclear parameters. Selection of
ariables for consideration for entry was based on both
nivariate statistical significance and clinical judgment
17). The threshold for entry of variables into the final
odel was p  0.05. A statistically significant increase in
he global chi-square of the model after the addition of
he tested variables defined incremental prognostic value.
odel assumptions of proportional hazards, linearity,
nd additivity were examined, and risk-adjusted survival
nd predicted CD rates were determined on the basis of
he final model. Kaplan-Meier analysis was used to depict
isk-adjusted cumulative CD-free survival curves com-
aring patients among the following clinical subsets: 1)
on-AF patients with normal MPS; 2) AF patients with
ormal MPS; 3) non-AF patients with abnormal MPS; And 4) AF patients with abnormal MPS. Statistical
nalysis used SPSS for Windows (version 11.0, SPSS
nc., Chicago, Illinois).
ESULTS
atient characteristics. Within our patient population, the
revalence of AF rose significantly with age (Fig. 1). As
hown in Table 1, the AF patient cohort was significantly
lder than our non-AF cohort, by a mean of approximately
ight years. Compared with non-AF cohort, our AF cohort
lso underwent more vasodilator than exercise stress, had an
% greater mean incidence of hypertension, and a higher
requency of dyspnea. In addition, the frequency of non-
iagnostic ECGs was two-fold higher in the AF cohort.
trial fibrillation patients more frequently had resting
achycardia (rest heart rate 100 beats/min), and almost
alf of the AF cohort was under the influence of digoxin
uring MPS. Only a small percentage of patients in both
ohorts was under the influence of beta-blockers or calcium-
hannel blockers during stress testing.
ollow-up events. The unadjusted CD rate was more than
hree-fold higher among the AF versus non-AF patients,
uring a mean follow-up period spanning 2.21  1.15 years
Table 2). By contrast, there were no differences in the
on-fatal MI rate between the two groups. Patients with
F had almost three-fold higher rate of noncardiac death
ompared with non-AF patients (Table 2). Furthering the
ultivariable analysis of cardiac events, we compared only
he CD rate in the AF and non-AF groups.
PS results in patients with and without AF. Compared
ith the non-AF patients, the patients with AF had greater
Myo fixed values but comparable % Myo ischemic values
igure 1. Prevalence of atrial fibrillation (AF) in the study population as a
unction of age. *p  0.001 across groups. Solid bars  percentage of AF
atients.
able 2. Distribution of Follow-up Events in the
tudy Population
Outcome Events
AF Patients
(n  384)
Non-AF Patients
(n  15,664) p Value
D 34 (4.0%/yr) 431 (1.3%/yr) 0.001
on-fatal MI 8 (1.0%/yr) 373 (1.1%/yr) 0.705
on-cardiac death 43 (5.1%/yr) 604 (1.8%/yr) 0.001F  atrial fibrillation; CD  cardiac death; MI  myocardial infarction.
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September 1, 2004:1062–70 Atrial Fibrillation and Prognosis in SPECTFig. 2). Accordingly, the higher % Myo stress values noted
n the AF patients were due almost entirely to greater %
yo fixed values.
D rate as function of MPS results. Atrial fibrillation
emained a significant predictor of outcome after dividing
ur patient population into normal, mildly abnormal, and
oderately to severely abnormal MPS subgroups, as illus-
rated in Figure 3. Those with AF had a substantially
reater event rate in all MPS categories.
D rate in different clinical subsets of AF and non-AF
atients. When patients were divided on the basis of
arious clinical variables, such as age, the type of stress, and
he presence or absence of diabetes, of shortness of breath,
r of resting tachycardia, AF patients had a higher incidence
f cardiac events in all subgroups (Table 3). Of note, 18%
mong AF cohort had rest HR 100 beats/min, compared
ith only 2.5% of patients without AF; in both patients
ith and without AF, this HR elevation was associated with
relatively high cardiac event rate. By contrast, among
atients without such rest HR elevation, only the AF
ubgroup had a significant increase in cardiac events.
nivariable and multivariable analysis. The most power-
ul univariable predictor of adverse outcome in the study
opulation was an abnormal MPS, associated with a seven-fold
ncrease in the risk of CD compared with patients who had a
igure 2. Myocardial perfusion single-photon emission computed tomog-
aphy results in the study population. *p  0.007; **p  0.002 compared
ith non-atrial fibrillation (AF) patients. % Myo fixed  % myocardium
ypoperfused at rest (from summed rest score); % Myo ischemic  %
yocardium ischemic (from summed difference perfusion score); % Myo
tress % myocardium hypoperfused at stress (from summed stress score).
olid bars  AF; open bars  non-AF.
Table 3. CD Rate by Presence of AF in Differ
Clinical Subset
AF
(n
Age 75 yrs (n  12,530) 2.9%
Age 75 yrs 5.6%
Exercise stress (n  10,842) 2.7%
Vasodilator stress (n  5,206) 5.1%
Rest HR 100 beats/min (n  465) 3.3%
Rest HR 100 beats/min (n  15,583) 4.2%
No diabetes (n  13,671) 3.6%
Diabetes (n  2,377) 5.8%
No SOB (n  15,168) 3.8%
SOB (n  879) 5.3%AF  atrial fibrillation; CD  cardiac death; HR  heart rate; Sormal perfusion study (Table 4). Vasodilator stress, presence
f shortness of breath, AF, and age 75 years were also
ssociated with a strikingly high (3-fold) increase in risk of
D. By Cox proportional hazards analysis, the multivariable
odel most predictive of CD in the overall study population
ncluded AF as well as age, diabetes, shortness of breath, use of
asodilator stress, rest heart rate, and the nuclear variables (%
yo fixed and ischemic) (Table 5). By far, the most potent
ultivariable predictors of CD were % Myo fixed and isch-
mic. When added to the multivariable model in place of %
yo fixed and ischemic, % Myo stress also was a strong,
ndependent predictor of CD (p  0.001), and the global
hi-square for the overall model with this substitution was
,119 (p  0.001). Among the clinical variables, age and
asodilator stress were the most powerful independent predic-
ors of CD, followed by rest heart rate, shortness of breath,
iabetes, and presence of AF. This model included a nonlinear
erm for age. Of note, despite the higher prevalence of resting
achycardia in AF patients compared with non-AF group,
entioned in the preceding text, there was no prognostic
nteraction between these two variables by multivariable
nalysis.
igure 3. Unadjusted cardiac death (CD) rates in patients with atrial
brillation (AF) compared with non-AF patients as a function of myocar-
ial perfusion single-photon emission computed tomography results. *p 
.001. abnl  abnormal; Mod-Sev  moderately to severely; MPS 
yocardial perfusion single-photon emission computed tomography;
Myo Stress  % myocardium hypoperfused at stress (from summed
tress score). Solid bars  AF patients; open bars  non-AF patients.
linical Subsets of Patients
ients
84)
Non-AF Patients
(n  15,664) p Value
4/221) 0.8%/yr (208/12,309) 0.001
0/163) 3.0 (223/3,355) 0.043
0/170) 0.5%/yr (132/10,672) 0.001
4/214) 2.7%/yr (299/4,992) 0.001
/69) 3.0%/yr (26/396) 0.939
9/315) 1.2%/yr (405/15,268) 0.001
5/314) 1.0%/yr (307/13,357) 0.001
/70) 2.4%/yr (124/2,307) 0.006
7/324) 1.1%/yr (356/14,845) 0.001
/60) 4.2%/yr (75/819) 0.552ent C
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Atrial Fibrillation and Prognosis in SPECT September 1, 2004:1062–70omparison of risk-adjusted CD rates. To further assess
he impact of clinical factors on outcome among AF and
on-AF cohorts, we performed risk-adjusted Kaplan-Meier
urvival curves by MPS results (Fig. 4). Predicted survival of
F patients was significantly worse compared with non-AF
atients (p  0.001) either in normal and abnormal MPS,
ven after adjustment for all independent predictors that
ere identified in the final Cox model, including age, %
yo fixed and ischemic, shortness of breath, rest heart rate,
iabetes, and type of stress.
rognostic significance AF in patients with normal and
mpaired left ventricular function. Among the 4,239
atients who had LVEF assessment performed by gated
PECT imaging, there were 86 AF patients (22.2% of AF
roup) and 4,153 non-AF patients (26.5% of non-AF
roup). While patients with AF in this cohort were older
nd generally sicker than their non-AF counterparts (as
reviously noted in our larger overall patient group), the AF
able 4. Significant Unavailable Predictors of Cardiac Death in
he Study Population
Variables OR (95% CI Limits) p Value
ale gender (n  9,508) 1.31 (1.08–1.59) 0.006
iabetes (n  2,377) 2.38 (1.94–2.93) 0.001
ypertension (n  7,596) 1.40 (1.16–1.69) 0.001
OB (n  879) 3.97 (3.10–5.10) 0.001
F (n  384) 3.43 (2.38–4.95) 0.001
est HR 100 beats/min
(n  465)
2.49 (1.71–3.63) 0.001
asodilator stress (n  5,206) 4.98 (4.08–6.09) 0.001
bnormal MPS (n  6,027) 7.12 (5.65–8.97) 0.001
ge 75 yrs (n  3,518) 4.11 (3.41–4.96) 0.001
rior PCI (n  1,907) 1.42 (1.10–1.83) 0.008
rior CABG (n  2,177) 2.60 (2.11–3.19) 0.001
rior MI (n  3,041) 2.60 (2.15–3.15) 0.001
I  confidence interval; MPS  myocardial perfusion SPECT; OR  odds ratios.
igure 4. Risk-adjusted cardiac death (CD)-free survival curves of patients
ith atrial fibrillation (AF) compared with non-AF patients. Solid lines
F patients; dotted lines  non-AF patients. 1  non-AF patients with
ormal myocardial perfusion single-photon emission computed tomogra-
hy (MPS); 2 AF patients with normal MPS; 3 non-AF patients with
bnormal MPS; 4  AF patients with abnormal MPS.wther abbreviations as in Table 1.nd non-AF patients in this cohort did not differ signifi-
antly from the larger sample of AF and non-AF patients
ithin our study (Table 6). Although the percentage of
atients with a history of prior myocardial infarction was the
ame in both the AF and non-AF cohorts, the AF patients
ad a lower mean resting LVEF value and a higher
ercentage of patients with an LVEF 35%.
Notably, as indicated in Figure 5, when LVEF was
ichotomized (as 35% or 35%), the frequency of CD
as significantly increased in the AF patients in both LVEF
ubgroups, but the relative risk of CD was more prominent
n AF patients compared with non-AF patients with pre-
erved LV function.
Further, when added in stepwise fashion to our multivar-
ate model (i.e., only after considering all of the significant
linical variables, nuclear perfusion variables [SRS and
DS], and the LVEF), the presence or absence of AF added
ignificantly (p  0.014) to the global chi-square value for
rediction of CD (Fig. 6). This was true even though
VEF, entered as a continuous variable, was a significant
ndependent predictor of CD (p  0.001) among the
ubgroup of patients who underwent gated SPECT assess-
ent. Adding other variables (history of hypertension, prior
yocardial infarction, or revascularization) to the model
hat already included AF did not reveal any significant
ncrease in predictive value of the model.
ISCUSSION
his is the first study to examine the interaction between
F and the results of stress-rest MPS for predicting cardiac
utcomes. The reason why such studies have been lacking
reviously is evident from the fact that our follow-up of over
6,000 subjects contained only 384 patients with AF. On
he other hand, while AF in the overall population was
ncommon, the incidence of AF neared 5% among our
atients, who were 75 years old, a subgroup that is
ncreasingly being referred for cardiac stress testing.
Our principal finding was the observation that AF was
ssociated with a significantly increased CD rate among
ach of our relevant SPECT subgroups. Among patients
able 5. Final Multivariable Cox Proportional Hazards Model
Global Chi-Square of the Model  1,146.1, p  0.001)
Variable in Model Chi-Square p Value
ge* 57.9 0.001
iabetes 15.0 0.001
OB 17.9 0.001
asodilator stress 64.5 0.001
Myo fixed 264.6 0.001
Myo ischemic 125.7 0.001
est HR 17.9 0.001
F 7.5 0.006
Variable shows nonlinearity.
% Myo fixed  % myocardium hypoperfused at rest (from summed rest score);
Myo ischemic  % myocardium ischemic (from summed difference perfusion
core). Other abbreviations as in Table 1.ith an abnormal SPECT study, the CD rate was more
t
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September 1, 2004:1062–70 Atrial Fibrillation and Prognosis in SPECThan doubled if AF was present. When these abnormal
PECT patients were further divided into those with mild
nd relatively more severely abnormal SPECT studies, the
elationship between AF and elevated CD rates persisted.
mong patients with a normal SPECT study, the observed
unadjusted) CD rate rose from only 0.4% per year in those
ithout AF to 1.6% per year among those with AF. The
atter rate places patients into the intermediate risk category,
oth according to Framingham risk score analysis (29,30)
nd conventional practice (11–17). By multivariable analysis
n the subgroup having gated SPECT, AF demonstrated
ncremental prognostic value not only over clinical and
uclear variables, but also over LVEF in predicting CD. Of
ote, observed CD rates were substantially higher in AF
atients compared with non-AF patients, regardless of the
resence or absence of severe LV dysfunction.
rior studies. Chronic AF has generally been associated
ith substantial morbidity and decreased survival (31),
lthough it is not clear if AF, per se, results in excess
ortality.
Table 6. Clinical Characteristics of the Study P
Function Assessed by Gated SPECT
Parameters
Gender (male)
Age (mean  SD)
Vasodilator stress
Prior MI
Prior CABG
Prior PCI
Hypertension
Diabetes
SOB
Angina
LVEF (mean  SD)
LV dysfunction (LVEF 35%)
Resting tachycardia (rest HR 100 beats/min)
Beta-blockers*
Calcium-channel blockers*
Digoxin*
*Under influence at the time of testing.
AF atrial fibrillation; Angina typical or atypical angin
rate; LV left ventricle; LVEF post-stress left ventricular
coronary intervention; SOB  shortness of breath.
igure 5. Unadjusted cardiac death (CD) rates in patients with atrial
brillation (AF) compared with non-AF patients as a function of left
entricular ejection fraction. *p 0.001. EF ejection fraction. Solid barsAF patients; open bars  non-AF patients. cPrevious studies have shown that the overall mortality
ate in patients with AF is at least doubled (2,7,9). Whether
ortality is directly influenced by AF or AF is a conse-
uence of underlying disease is unclear, including subsets of
atients who were admitted for the first time with AF (32),
lderly subjects (33), postmyocardial infarction patients
34), patients with advanced heart failure (35), patients with
symptomatic and symptomatic left ventricular dysfunction
10), with pacemakers (36), and even those with implantable
ardioverter-defibrillators (37). In some subsets, AF, how-
ver, has not been associated with a poor prognosis. For
lation Patients Having Left Ventricular
F Group
n  86)
Non-AF Group
(n  4,153) p Value
(60.5%) 2,357 (56.8%) 0.492
6 9.4 65.3  12.6 0.001
(59.3%) 1,592 (38.3%) 0.001
(17.4%) 734(17.7%) 0.955
(17.4%) 550 (13.2%) 0.257
(10.8%) 1,940 (12.6%) 0.290
(61.6%) 2,019 (48.6%) 0.017
(27.9%) 613 (14.8%) 0.001
(23.3%) 305 (7.3%) 0.001
(39.5%) 1,976 (47.6%) 0.139
0 15.2 58.7  14.7 0.001
(18.6%) 325 (7.8%) 0.001
(15.1%) 102 (2.5%) 0.001
(7.0%) 403 (9.7%) 0.397
(7.0%) 321 (7.7%) 0.796
(33.7%) 187 (4.5%) 0.001
story; CABG coronary artery bypass grafting; HR heart
n fraction; MImyocardial infarction; PCI percutaneous
igure 6. Incremental prognostic value of chronic atrial fibrillation (AF) in
redicting cardiac death over clinical variables (*age, type of stress, resting
eart rate, diabetes, and shortness of breath), nuclear variables (% myocar-
ium hypoperfused at rest [% Myo fixed] and % myocardium ischemic [%
yo ischemic]), left ventricular ejection function ([LVEF] *including the
nteraction LVEF  shortness of breath). Added to all these most
ignificant variables, AF provided additional significant gain in globalopu
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oted in the Vasodilator Heart Failure Trial (V-HeFT) (38)
nd two other relatively small studies of heart failure
atients (39,40). Still, among recent large trials, such as a
andom Swedish population sample of 7,495 men age 47 to
5 years (41), AF was associated with a 3.3 increase in
ortality. Also, data from the Framingham Heart Study
emonstrated that AF was associated with excess mortality
mong men and women independent of associated cardiac
onditions and risk factors (42). In this study, the risk of
ortality conferred by AF did not vary by age or gender and
as present even in the absence of valvular disease or
reexisting cardiovascular condition.
Notably, none of prior studies attempted to relate MPS
ndings to outcome among AF patients. Our study dem-
nstrates that AF is independently predictive of worse
utcome even after taking into account consideration of
oth the magnitude of myocardial scar and ischemia and a
ariety of powerful clinical variables.
Of note, in the current manuscript we reported MPS
esults as percentage of myocardium hypoperfused (summed
erfusion score normalized by the maximum possible score
n the model of the left ventricle). The benefits of this
pproach include that the percentage of myocardium hy-
operfused provides a validated measure with intuitive
linical implications and that can easily be applied with
coring systems using varying numbers of segments (27,28).
otential mechanisms. The association between AF and
ncreased cardiac events among our various MPS subgroups
ould be due either to a direct mechanism or an indirect
ssociation. With respect to the latter, AF could simply be
erving as a marker for severe disease, where the disease
arameters, per se, and not AF, are the direct contributors
o the heightened death rate in our AF cohort. Along these
ines, the AF patients in our study were older, had more
ypertension, more dyspnea, more resting ECG abnormal-
ties, and a higher frequency of resting tachycardia (43)
ompared with the patients without AF, with a number of
hese factors having figured prominently as prior risk mod-
fiers. The AF patients also had a higher noncardiac death
ate. Moreover, compared with the patients without AF, AF
atients had a higher prevalence of severe LV dysfunction
LVEF 35%), and more resting perfusion abnormalities,
espite the same percentage of patients with history of prior
yocardial infarction. Thus, both clinically and function-
lly, patients with AF represented a population that was
ntrinsically sicker compared with non-AF group.
On the other hand, several observations in our study raise
he possibility that AF may be contributing to a heightened
D rate through a more direct mechanism. First, we
ivided our patients into subgroups based on the most
ignificant multivariate predictors of CD, including age,
istory of dyspnea, diabetes, presence of resting tachycardia,
ype of stress patients were able to tolerate (exercise vs.
asodilator). In each subgroup, the patients with AF had a
ignificantly higher CD rate than the corresponding ion-AF patients. Second, we examined the possibility that,
hereas no single clinical factor accounted for the height-
ned CD rate among patients with AF, a combination of
linical factors could explain the difference. To that end, we
erformed a risk-adjusted Kaplan-Meier survival curve
nalysis in which we compared CD rates after adjusting for
ll of the independent Cox model predictors of CD. This
isk-adjusted analysis still resulted in a significantly greater
D rate in AF versus non-AF patients both in normal and
bnormal MPS subgroups. Thus, AF remained a significant
ndependent prognostic predictor even after adjustment for
ll other known prognostic modifiers. Finally, even when
he most powerful prognostic variables (perfusion scores and
VEF) were entered into the model in the group who had
ated SPECT, AF demonstrated additional significant
ncremental value in predicting CD.
However, the direct pathophysiologic mechanism
hrough which AF might be contributing to an increased
D rate remains to be determined. Although prior obser-
ations suggest that the presence of AF may be associated
ith the development of an occult or clinically unrecognized
ardiomyopathy (44) and/or heart failure (10), our findings
hat AF was of prognostic importance even after LVEF was
onsidered suggest that this mechanism alone does not
xplain the expanded risk. Many other possible explanations
esides AF-induced tachycardia could potentially help ex-
lain the heightened cardiovascular risk in such patients,
ncluding enhanced neurohumoral stimulation (45), hyper-
oaguability (46), the propensity of AF patients to have a
igher frequency of serious ventricular arrhythmias (47),
ncreased inflammation (48), a direct AF-induced reduction
n coronary flow reserve (49), and AF-induced endothelial
ysfunction (50).
linical implications. Our findings indicate that the pres-
nce or absence of AF should be considered when inter-
reting the results of MPS. Previous studies have demon-
trated that patients with normal MPS have a 1% annual
isk of cardiac events (16); however, the intermediate risk
bserved in our AF patients with normal MPS studies
uggests that such patients should be followed more closely
han the average normal MPS patient, including scrutiny for
ll modifiable coronary artery disease risk factors and/or
onsideration of measures that may maximally preserve left
entricular function. In a similar vein, there are other
ormal MPS patients with intermediate risk for events,
ncluding diabetics (51), patients with a low resting LVEF
52), and patients in whom a normal MPS study is discor-
ant with clinical data strongly suggestive of ischemia (53).
hese are also clinical subsets that deserve more scrutiny
ompared with the average patient with a normal MPS
tudy.
Our findings apply similarly for the management of AF
atients with mildly abnormal MPS studies. While we have
reviously observed that patients with mildly abnormal
PS (2–8) are at low risk for CD (14), this was not the casen our AF cohort with these findings; the CD rate was 6.3%
p
c
t
A
m
a
S
r
b
e
f
a
u
a
S
w
i
c
v
c
d
o
b
v
h
w
(
p
t
s
u
s
a
c
b
t
C
A
a
i
f
e
w
d
q
R
D
B
C
R
1
1
1
1
1
1
1
1
1069JACC Vol. 44, No. 5, 2004 Abidov et al.
September 1, 2004:1062–70 Atrial Fibrillation and Prognosis in SPECTer year in the AF patients with mildly abnormal MPS
ompared with 1.2% per year in the non-AF group with
hese MPS findings. Whether this means that patients with
F and mild ischemic abnormalities constitute a group
ore deserving of early referral to cardiac catheterization is
question warranting further study.
tudy limitations. Our results are based on a population
eferred for nuclear testing and may not be applicable to a
roader population. Although all data were collected and
ntered prospectively, the study is retrospective. Ventricular
unction was assessed in only 26.4% of the study population,
s gated MPS was not routinely performed in our laboratory
ntil 1995. However, there was no significant difference in
ny observed variables in the patients studied with gated
PECT compared with the overall study population.
In our study, we presume that the majority of our patients
ith left ventricular dysfunction had either hypertensive or
schemic cardiomyopathy, because we intentionally ex-
luded patients with clinically apparent cardiomyopathies or
alvular disease, as done in other studies (54). However, we
annot exclude that some patients had undetected valvular
isease. Regardless, our findings indicate that the presence
f AF predicted worse outcomes among patients stratified
y summed rest defect score, a measure of the degree of left
entricular scarring, and according to LVEF levels.
While the accuracy of gated SPECT LVEF is not as
igh in AF as in patients without AF, good correlations
ith LVEF and other modalities has been demonstrated
55,56).
Although our total sample size was quite large, the overall
ercentage of patients with AF was relatively low, consti-
uting only 2.4% of our patient population. Thus, additional
tudy involving more AF patients in the follow-up would be
seful, to assess the robustness of observations noted in our
tudy. Nevertheless, prevalence of AF in our population by
ge was pretty similar to this in general population.
Finally, this study is based on data from a single nuclear
ardiology center. Future study in this area may, thus,
enefit from pooling the data from multiple medical centers,
o increase the sample size of AF patients.
onclusions. Our findings indicate that the patients with
F warrant special consideration with respect to prognostic
ssessment using MPS. The presence of AF independently
ncreases the risk of cardiac events over perfusion and
unction variables. Patients with AF have a high risk of CD,
ven when MPS is only mildly abnormal. Whether patients
ith AF and mildly abnormal MPS constitute a group more
eserving of early referral to cardiac catherization is a
uestion warranting further study.
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